Next Article in Journal
Morphology of Donor and Recipient Nerves Utilised in Nerve Transfers to Restore Upper Limb Function in Cervical Spinal Cord Injury
Next Article in Special Issue
Overview of Traumatic Brain Injury: An Immunological Context
Previous Article in Journal
Deep Brain Stimulation: In Search of Reliable Instruments for Assessing Complex Personality-Related Changes
Previous Article in Special Issue
Stress and Withdrawal from Chronic Ethanol Induce Selective Changes in Neuroimmune mRNAs in Differing Brain Sites
Article Menu

Export Article

Open AccessReview
Brain Sci. 2016, 6(4), 41; doi:10.3390/brainsci6040041

Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson’s Disease

1
Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
2
Sanders-Brown Center on Aging, Department of Anatomy and Neurobiology, University of Kentucky, Lexington, KY 40508, USA
3
Byrd Alzheimer’s Institute, Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33613, USA
4
James A Haley VA Hospital, 13000 Bruce B Downs Blvd, Tampa, FL 33612, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Donna Gruol
Received: 9 July 2016 / Revised: 6 September 2016 / Accepted: 20 September 2016 / Published: 23 September 2016
(This article belongs to the Special Issue Advances in Neuroimmunology)
View Full-Text   |   Download PDF [587 KB, uploaded 23 September 2016]   |  

Abstract

Parkinson’s disease (PD) is a common neurodegenerative disorder that primarily afflicts the elderly. It is characterized by motor dysfunction due to extensive neuron loss in the substantia nigra pars compacta. There are multiple biological processes that are negatively impacted during the pathogenesis of PD, and are implicated in the cell death in this region. Neuroinflammation is evidently involved in PD pathology and mitigating the inflammatory cascade has been a therapeutic strategy. Age is the number one risk factor for PD and thus needs to be considered in the context of disease pathology. Here, we discuss the role of neuroinflammation within the context of aging as it applies to the development of PD, and the potential for two representative compounds, fractalkine and astaxanthin, to attenuate the pathophysiology that modulates neurodegeneration that occurs in Parkinson’s disease. View Full-Text
Keywords: Parkinson’s disease; neuroinflammation; microglia; fractalkine; astaxanthin Parkinson’s disease; neuroinflammation; microglia; fractalkine; astaxanthin
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Grimmig, B.; Morganti, J.; Nash, K.; Bickford, P.C. Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson’s Disease. Brain Sci. 2016, 6, 41.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Brain Sci. EISSN 2076-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top